… to compare the clinical outcomes of gefitinib-treated and erlotinib-treated patients with
advanced/metastatic or recurrent NSCLC harboring an EGFR mutation in either exon 19 or 21. …

… patients with either 19 or 21 exon alterations, patient characteristics (age, sex, ethnicity,
smoking status; tumour histology; Eastern Cooperative Oncology Group performance status) and …

… Conclusions: Non-LRE deletions in exon 19 were associated with worse … clinical outcome
under EGFR TKIs depends on not only the existence but also the types of deletions in exon 19. …

… Real-world clinical outcomes in patients with advanced NSCLC harboring EGFR exon 20
insertion (… We conducted a retrospective cohort study to assess the clinical outcomes of EGFR …

… 44 will result in a significantly better outcome than skipping of exon 46. Similarly, our data
suggest that multiexon skipping of either exons 46 to 47 or 46 to 48 is likely to result in a better …

… exon 19 and exon 21 mutations. , 15 This study investigated the differential clinical outcomes
… B, PFS for patients with either exon 19 deletion or L858R mutation. C, PFS for patients with …

… ) mutations, including a known exon 19 deletion (19 del) and exon 21 L858R point mutation
(… This study aimed to investigate the clinical outcomes of EGFR-TKI treatment in patients with …

… found to have either EGFR exon 19 deletion or EGFR L858R. The clinical characteristics
of … tumor histology were found to have an EGFR exon 19 deletion. Of the 70 patients with …

… exon 19 or 21 was not performed. However, samples with complete sequencing of exon
19 and 21 but with incomplete analysis of either exon 18 or exon 19 were reported as wild-type. …

… In the FLAURA study that compared osimertinib with either erlotinib or gefitinib in previously
… other clinical outcomes in the three patient groups described above. Clinical outcomes of …